Skip to main content
. Author manuscript; available in PMC: 2017 Aug 23.
Published in final edited form as: Mol Cancer Res. 2011 Feb 2;9(3):364–374. doi: 10.1158/1541-7786.MCR-10-0526

Figure 4. ESC8 kills ER- breast cancer cells by manipulating PI3K-Akt pathway.

Figure 4

a. MDA-MB-231 cells were pre-treated with 20µM LY294002 (LY20) (black bar) or untreated cells (white bar) treated with ESC8 and viability of cells were assayed (* p< 0.005), (n=6). b. In MDA-MB-231 cells, a 1 µM ESC8 treatment blocked mTOR phosphorylation at ser-2448 and its kinase activity, as determined by Western blot with antibodies against p-mTOR and p-p70S6 kinase. In contrast, a 10 µM dose of ESC8 in MDA-MB-231 cells induced phosphorylation of Akt-1/2/3 at ser-473. β-Actin was used as a loading control. The relative fold expressions of protein levels have been indicated as required. Figures represent three separate experiments with similar results.